W. J. Slichenmyer and D. W. Fry, Anticancer therapy targeting the erbB family of receptor tyrosine kinases, Seminars in Oncology, vol.28, issue.5, pp.67-79, 2001.
DOI : 10.1016/S0093-7754(01)90284-2

M. Schmidt, Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing, Breast Cancer Research, vol.7, issue.2, pp.256-66, 2005.
DOI : 10.1186/bcr991

M. Martin, Randomized Phase 3 Trial of Fluorouracil, Epirubicin, and Cyclophosphamide Alone or Followed by Paclitaxel for Early Breast Cancer, JNCI Journal of the National Cancer Institute, vol.100, issue.11, pp.100-805, 2008.
DOI : 10.1093/jnci/djn151

J. S. Ross and J. A. Fletcher, The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy, Oncologist, vol.3, issue.4, pp.237-252, 1998.

G. E. Peoples, Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide., Proceedings of the National Academy of Sciences, vol.92, issue.2, pp.432-436, 1995.
DOI : 10.1073/pnas.92.2.432

D. J. Slamon, Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2, New England Journal of Medicine, vol.344, issue.11, pp.344-783, 2001.
DOI : 10.1056/NEJM200103153441101

R. Nahta and F. J. Esteva, Herceptin: mechanisms of action and resistance, Cancer Letters, vol.232, issue.2, pp.123-161, 2006.
DOI : 10.1016/j.canlet.2005.01.041

K. Berns, A Functional Genetic Approach Identifies the PI3K Pathway as a Major Determinant of Trastuzumab Resistance in Breast Cancer, Cancer Cell, vol.12, issue.4, pp.395-402, 2007.
DOI : 10.1016/j.ccr.2007.08.030

M. A. Cobleigh, Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study, J Clin Oncol Br J Cancer, vol.17, issue.97, pp.94-1016, 1999.

M. L. Disis, Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer, Cancer Res, vol.54, issue.1, pp.16-20, 1994.

B. Fisk, Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines, Journal of Experimental Medicine, vol.181, issue.6, pp.181-2109, 1995.
DOI : 10.1084/jem.181.6.2109

M. L. Disis, Granulocyte-macrophage colony-stimulating factor: an effective adjuvant for protein and peptide-based vaccines, Blood, vol.88, pp.202-210, 1996.

C. H. Huber and T. Wolfel, Immunotherapy of cancer: from vision to standard clinical practice, J Cancer Res Clin Oncol, vol.130, issue.7, pp.367-74, 2004.

A. Dols, Vaccination of Women with Metastatic Breast Cancer, Using a Costimulatory Gene (CD80)-Modified, HLA-A2-Matched, Allogeneic, Breast Cancer Cell Line: Clinical and Immunological Results, Human Gene Therapy, vol.14, issue.11, pp.14-1117, 2003.
DOI : 10.1089/104303403322124828

A. Dols, Identification of Tumor-Specific Antibodies in Patients With Breast Cancer Vaccinated With Gene-Modified Allogeneic Tumor Cells, Journal of Immunotherapy, vol.26, issue.2, pp.163-70, 2003.
DOI : 10.1097/00002371-200303000-00009

J. W. Park, Treatment With Autologous Antigen-Presenting Cells Activated With the HER-2 ???Based Antigen Lapuleucel-T: Results of a Phase I Study in Immunologic and Clinical Activity in HER-2???Overexpressing Breast Cancer, Journal of Clinical Oncology, vol.25, issue.24, pp.25-3680, 2007.
DOI : 10.1200/JCO.2006.10.5718

H. Bernhard, Adoptive transfer of autologous, HER2-specific, cytotoxic T lymphocytes for the treatment of HER2-overexpressing breast cancer, Cancer Immunology, Immunotherapy, vol.115, issue.2, pp.271-80, 2008.
DOI : 10.1007/s00262-007-0355-7

Y. Sakai, Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice, Cancer Research, vol.64, issue.21, pp.64-8022, 2004.
DOI : 10.1158/0008-5472.CAN-03-3442

Y. Chen, Induction of ErbB-2/neu-specific protective and therapeutic antitumor immunity using genetically modified dendritic cells: enhanced efficacy by cotransduction of gene encoding IL-12, Gene Therapy, vol.8, issue.4, pp.316-339, 2001.
DOI : 10.1038/sj.gt.3301396

Z. Chen, Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor, Cancer Gene Therapy, vol.9, issue.9, pp.778-86, 2002.
DOI : 10.1038/sj.cgt.7700498

P. Brossart, Induction of cytotoxic T-lymphocyte responses in vivo after vaccinations with peptide-pulsed dendritic cells, Blood, vol.96, issue.9, pp.3102-3110, 2000.

B. J. Czerniecki, Targeting HER-2/neu in Early Breast Cancer Development Using Dendritic Cells with Staged Interleukin-12 Burst Secretion, Cancer Research, vol.67, issue.4, pp.1842-52, 2007.
DOI : 10.1158/0008-5472.CAN-06-4038

M. Campbell, An adenoviral vector containing an arg???gly???asp (RGD) motif in the fiber knob enhances protein product levels from transgenes refractory to expression, Cancer Gene Therapy, vol.10, issue.7, pp.559-70, 2003.
DOI : 10.1038/sj.cgt.7700599

S. Sas, Vaccination of fiber-modified adenovirus-transfected dendritic cells to express HER-2/neu stimulates efficient HER-2/neu-specific humoral and CTL responses and reduces breast carcinogenesis in transgenic mice, Cancer Gene Therapy, vol.60, issue.10, pp.15-655, 2008.
DOI : 10.1158/0008-5472.CAN-04-1081

T. Chan, HER-2/neu-gene engineered dendritic cell vaccine stimulates stronger HER-2/neu-specific immune responses compared to DNA vaccination, Gene Therapy, vol.4, issue.19, pp.13-1391, 2006.
DOI : 10.1038/sj.gt.3302797

C. T. Viehl, A Tat Fusion Protein???Based Tumor Vaccine for Breast Cancer, Annals of Surgical Oncology, vol.198, issue.Suppl 2, pp.517-542, 2005.
DOI : 10.1245/ASO.2005.06.028

W. Z. Wei, Protection against mammary tumor growth by vaccination with full-length, modified humanErbB-2 DNA, International Journal of Cancer, vol.54, issue.5, pp.748-54, 1999.
DOI : 10.1002/(SICI)1097-0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6

S. A. Pilon, M. P. Piechocki, and W. Z. Wei, Vaccination with Cytoplasmic ErbB-2 DNA Protects Mice from Mammary Tumor Growth Without Anti-ErbB-2 Antibody, The Journal of Immunology, vol.167, issue.6, pp.3201-3206, 2001.
DOI : 10.4049/jimmunol.167.6.3201

M. P. Piechocki, S. A. Pilon, and W. Z. Wei, Complementary Antitumor Immunity Induced by Plasmid DNA Encoding Secreted and Cytoplasmic Human ErbB-2, The Journal of Immunology, vol.167, issue.6, pp.3367-74, 2001.
DOI : 10.4049/jimmunol.167.6.3367

W. Z. Wei, Concurrent Induction of Antitumor Immunity and Autoimmune Thyroiditis in CD4+CD25+ Regulatory T Cell-Depleted Mice, Cancer Research, vol.65, issue.18, pp.65-8471, 2005.
DOI : 10.1158/0008-5472.CAN-05-0934

J. Jacob, Activity of DNA vaccines encoding self or heterologous Her-2/neu in Her-2 or neu transgenic mice, Cellular Immunology, vol.240, issue.2, pp.96-106, 2006.
DOI : 10.1016/j.cellimm.2006.07.002

J. B. Jacob, Control of Her-2 Tumor Immunity and Thyroid Autoimmunity by MHC and Regulatory T Cells, Cancer Research, vol.67, issue.14, pp.67-7020, 2007.
DOI : 10.1158/0008-5472.CAN-06-4755

S. Rovero, DNA Vaccination Against Rat Her-2/Neu p185 More Effectively Inhibits Carcinogenesis Than Transplantable Carcinomas in Transgenic BALB/c Mice, The Journal of Immunology, vol.165, issue.9, pp.5133-5175, 2000.
DOI : 10.4049/jimmunol.165.9.5133

P. Gallo, Xenogeneic immunization in mice using HER2 DNA delivered by an adenoviral vector, International Journal of Cancer, vol.98, issue.1, pp.67-77, 2005.
DOI : 10.1002/ijc.20536

O. Radkevich-brown, Genetic regulation of the response to Her-2 DNA vaccination in human Her-2 transgenic mice Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine, Cancer Res J Clin Oncol J Clin Oncol, vol.69, issue.201110, pp.212-220, 2002.

M. L. Disis, Humoral Epitope-Spreading Following Immunization with a HER-2/neu Peptide Based Vaccine in Cancer Patients, Journal of Clinical Immunology, vol.24, issue.5, pp.571-579, 2004.
DOI : 10.1023/B:JOCI.0000040928.67495.52

K. L. Knutson, K. Schiffman, and M. L. Disis, Immunization with a HER-2/neu helper peptide vaccine generates HER-2/neu CD8 T-cell immunity in cancer patients, Journal of Clinical Investigation, vol.107, issue.4, pp.477-84, 2001.
DOI : 10.1172/JCI11752

L. H. Butterfield, Determinant spreading associated with clinical response in dendritic cellbased immunotherapy for malignant melanoma, Clin Cancer Res, issue.93, pp.998-1008, 2003.

M. L. Disis, J. Strickler, D. Wallace, V. Goodell, G. Salazar et al., Cellular immune parameters associated with improved long-term survival in advanced stage breast cancer patients after active immunization with a HER2-specific vaccine, Journal of Clinical Oncology, vol.26, issue.15_suppl, 2008.
DOI : 10.1200/jco.2008.26.15_suppl.3015

D. J. Webster, J. Waisman, B. Macleod, D. Rosa, C. Higgins et al., A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine, J Clin Oncol, issue.20, pp.26-3426, 2006.

E. A. Mittendorf, The E75 HER2/neu peptide vaccine, Cancer Immunology, Immunotherapy, vol.13, issue.10, pp.1511-1532, 2008.
DOI : 10.1007/s00262-008-0540-3

J. Lustgarten, Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8, Human Immunology, vol.52, issue.2, pp.109-118, 1997.
DOI : 10.1016/S0198-8859(96)00292-3

B. W. Anderson, Peptide priming of cytolytic activity to HER-2 epitope 369-377 in healthy individuals, Clin Cancer Res, issue.611, pp.4192-200, 2000.

K. L. Knutson, Immunization of cancer patients with a HER-2/neu, HLA-A2 peptide, p369- 377, results in short-lived peptide-specific immunity, Clin Cancer Res, vol.8, issue.5, pp.1014-1022, 2002.

J. L. Murray, Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer Immunization with a peptide epitope (p369-377) from HER-2/neu leads to peptide-specific cytotoxic T lymphocytes that fail to recognize HER-2/neu+ tumors, Clin Cancer Res Cancer Res, vol.8, issue.5021, pp.3407-3425, 1998.

G. E. Peoples, Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients Combined Clinical Trial Results of a HER2/neu (E75) Vaccine for the Prevention of Recurrence in High-Risk Breast Cancer Patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02, J Clin Oncol Clin Cancer Res, vol.23, issue.303, pp.7536-7581, 2005.

M. T. Hueman, Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine???, Breast Cancer Research and Treatment, vol.25, issue.Suppl 11, pp.17-29, 2006.
DOI : 10.1007/s10549-005-9108-5

J. Shimizu, S. Yamazaki, and S. Sakaguchi, Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity, J Immunol, issue.10, pp.163-5211, 1999.

E. A. Mittendorf, Investigating the Combination of Trastuzumab and HER2/neu Peptide Vaccines for the Treatment of Breast Cancer, Annals of Surgical Oncology, vol.24, issue.8, pp.13-1085, 2006.
DOI : 10.1245/ASO.2006.03.069

E. A. Mittendorf, Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial, Cancer, issue.11, pp.106-2309, 2006.

Y. L. Yip, Identification of Epitope Regions Recognized by Tumor Inhibitory and Stimulatory Anti-ErbB-2 Monoclonal Antibodies: Implications for Vaccine Design, The Journal of Immunology, vol.166, issue.8, pp.166-5271, 2001.
DOI : 10.4049/jimmunol.166.8.5271

N. K. Dakappagari, Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine, Cancer Res, issue.14, pp.60-3782, 2000.

N. K. Dakappagari, A Chimeric Multi-Human Epidermal Growth Factor Receptor-2 B Cell Epitope Peptide Vaccine Mediates Superior Antitumor Responses, The Journal of Immunology, vol.170, issue.8, pp.4242-53, 2003.
DOI : 10.4049/jimmunol.170.8.4242

H. S. Cho, Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab, Nature, vol.24, issue.6924, pp.421-756, 2003.
DOI : 10.1038/nature01392

J. T. Garrett, Novel Engineered Trastuzumab Conformational Epitopes Demonstrate In Vitro and In Vivo Antitumor Properties against HER-2/neu, The Journal of Immunology, vol.178, issue.11, pp.178-7120, 2007.
DOI : 10.4049/jimmunol.178.11.7120

A. B. Riemer, Generation of Peptide Mimics of the Epitope Recognized by Trastuzumab on the Oncogenic Protein Her-2/neu, The Journal of Immunology, vol.173, issue.1, pp.394-401, 2004.
DOI : 10.4049/jimmunol.173.1.394

J. Jasinska, Inhibition of tumor cell growth by antibodies induced after vaccination with peptides derived from the extracellular domain of Her-2/neu, International Journal of Cancer, vol.194, issue.6, pp.976-83, 2003.
DOI : 10.1002/ijc.11485

S. Wagner, Delayed tumor onset and reduced tumor growth progression after immunization with a Her-2/neu multi-peptide vaccine and IL-12 in c-neu transgenic mice, Breast Cancer Research and Treatment, vol.4, issue.1, pp.29-38, 2007.
DOI : 10.1007/s10549-006-9469-4

K. Azuma, Identification of HER2/neu-Derived Peptides Capable of Inducing both Cellular and Humoral Immune Responses in HLA-A24 Positive Breast Cancer Patients, Breast Cancer Research and Treatment, vol.94, issue.1, pp.19-29, 2004.
DOI : 10.1023/B:BREA.0000032920.95410.63

S. Limentani, T. Dorval, S. White, G. Curigliano, M. Campone et al., Phase I dose-escalation trial of a recombinant HER2 vaccine in patients with Stage II/III HER2+ breast cancer, Journal of Clinical Oncology, vol.23, issue.16_suppl, 2005.
DOI : 10.1200/jco.2005.23.16_suppl.2520

S. Kitano, HER2-Specific T-Cell Immune Responses in Patients Vaccinated with Truncated HER2 Protein Complexed with Nanogels of Cholesteryl Pullulan, Clinical Cancer Research, vol.12, issue.24, pp.12-7397, 2006.
DOI : 10.1158/1078-0432.CCR-06-1546

S. Kageyama, Humoral immune responses in patients vaccinated with 1???146 HER2 protein complexed with cholesteryl pullulan nanogel, Cancer Science, vol.88, issue.3, pp.601-608, 2008.
DOI : 10.1158/1078-0432.CCR-03-0706

R. Baral, Murine monoclonal anti-idiotypic antibody as a surrogate antigen for human Her-2/neu, International Journal of Cancer, vol.77, issue.1, pp.88-95, 2001.
DOI : 10.1002/1097-0215(200102)9999:9999<::AID-IJC1148>3.0.CO;2-9

M. Coelho, Isolation and characterisation of a human anti-idiotypic scFv used as a surrogate tumour antigen to elicit an anti-HER-2/neu humoral response in mice, British Journal of Cancer, vol.12, issue.10, pp.90-2032, 2004.
DOI : 10.1038/sj.bjc.6601825

K. Mohanty, Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu, Breast Cancer Research and Treatment, vol.12, issue.1, pp.1-11, 2007.
DOI : 10.1007/s10549-006-9391-9

S. Pal, Generation of Her-2/neu vaccine utilizing idiotypic network cascade, Cancer Biology & Therapy, vol.6, issue.12, pp.1916-1941, 2007.
DOI : 10.4161/cbt.6.12.4967